India, June 4 -- Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company, announced that its Arcotatug tavatecan, or IBI343, met its primary endpoint after the interim analysis of the Phase 3 study of Arcotatug Tavatecan in the treatment of previously treated locally advanced unresectable or metastatic CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma (G/GEJA) who have received at least two prior systemic therapies.
Gastric/gastroesophageal junction adenocarcinoma
Gastric cancer is the most common malignant tumor, and the 5-year survival rate of patients with metastatic gastric cancer is less than 5%. The company noted China and Japan as the areas with high gastric cancer incidence.
Currently, the standard tre...